Pathology: squamous - mNSCLC - L1 - all population;
squamous - mNSCLC - L1 - all population | |||||
IMpower-131 (ACnP), 2020 | IMpower-131 (ACP) EXPLORATORY, 2020 | CA184-104, 2017 | KEYNOTE-407, 2018 | ||
atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | |||
atezolizumab plus carboplatin plus paclitaxel | 1 | T1 | |||
pembrolizumab plus SoC | 1 | T1 | |||
ipilimumab plus SoC | 1 | T1 | |||
carboplatin plus nab-paclitaxel | 0 | T0 | |||
nab-paclitaxel | 0 | T0 | |||
placebo plus SoC | 0 | T0 | T0 |